Table 2.

Characteristics of patients who experienced cDLT.

ID	Age	Number of trastuzumab cycle	Baseline LVEF (%)	Nadir LVEF (%)	Relative GLS drop (%)	Hospitali- zation	Worst NYHA	Metastasis/ progression	Cumulative anthracycline dose (mg/m2)	Reason for permanent trastuzumab discontinuation
43	65	9	67.3	46.7	24.3	Yes	II	No	486*	Symptomatic severe mitral regurgitation
23	65	9	58.2	25.9	62	Yes	III	No	266	Continuous worsening of LV function with multi-valvular abnormalities
29	35	12	55	28	47	No	I	No	253	Continuous worsening of LV function

Note: Oncological outcomes and cardiac characteristics of patients who experience cardiac dose-limiting toxicity (cDLT).

^*Patient received high-dose epirubicin as part of the CEF protocol which is no longer in use.¹⁷ Epirubicin dose was converted to cardiotoxicity-equivalent doxorubicin dose.¹⁶